Edwards Lifesciences Corporation (ETR:EWL)

Intra-Cellular Therapies Ratios and Metrics

Market cap in millions EUR. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Aug 1, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	40,393	42,174	41,838	43,162	71,120	46,482
Market Cap Growth	-24.80%	0.80%	-3.07%	-39.31%	53.01%	7.20%
Enterprise Value	37,672	38,619	40,840	42,178	70,143	45,987
Last Close Price	68.64	72.37	69.22	70.05	115.30	-
PE Ratio	11.44	10.46	32.98	30.31	53.81	69.05
PS Ratio	8.34	8.03	9.23	10.33	15.46	12.96
PB Ratio	4.65	4.34	6.88	7.94	13.86	12.43
P/TBV Ratio	6.61	6.20	9.06	10.59	18.62	18.52
P/FCF Ratio	-	150.61	71.94	47.38	57.51	87.84
P/OCF Ratio	-	80.51	51.63	37.87	46.70	53.93
EV/Sales Ratio	7.65	7.35	9.01	10.10	15.25	12.83
EV/EBITDA Ratio	25.01	24.44	27.66	26.81	46.34	39.52
EV/EBIT Ratio	27.37	27.00	30.35	29.24	50.28	42.74
EV/FCF Ratio	-	137.92	70.23	46.30	56.73	86.91
Debt / Equity Ratio	0.07	0.07	0.10	0.12	0.12	0.15
Debt / EBITDA Ratio	0.40	0.42	0.41	0.40	0.39	0.48
Debt / FCF Ratio	-	2.42	1.07	0.71	0.49	1.07
Asset Turnover	-	0.49	0.57	0.53	0.67	0.64
Inventory Turnover	-	1.12	1.10	0.90	1.63	1.50
Quick Ratio	-	3.13	2.06	1.87	2.07	2.24
Current Ratio	-	4.18	3.38	3.03	3.08	3.46
Return on Equity (ROE)	-	16.64%	19.48%	22.74%	28.88%	18.88%
Return on Assets (ROA)	-	8.26%	10.53%	11.47%	12.60%	11.99%
Return on Capital (ROIC)	10.41%	10.19%	13.37%	14.80%	16.81%	16.30%
Return on Capital Employed (ROCE)	-	12.80%	18.20%	21.20%	21.20%	20.70%
Earnings Yield	8.74%	9.56%	3.03%	3.30%	1.86%	1.45%
FCF Yield	-	0.66%	1.39%	2.11%	1.74%	1.14%
Buyback Yield / Dilution	2.49%	1.66%	2.37%	1.11%	0.11%	0.75%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.